Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas

Trial Profile

Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Temozolomide (Primary) ; Benzylguanine; Carmustine; Filgrastim; Plerixafor
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2018 Planned primary completion date changed from 24 Mar 2018 to 24 Nov 2018.
    • 31 Aug 2018 Biomarkers information updated
    • 08 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 24 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top